Smyth et al. observed that the combination of anti-CTLA-4 and anti-RANKL demonstrated an antitumor activity in melanoma patients with bone metastases and found that the antitumor activity was dependent on lymphocytes in mouse model [88]. This evidence concerns the gene TNFSF11 and melanoma.